TNFRSF8 and Hodgkins lymphoma: Currently, the CD30-targeted ADCs brentuximab-vedotin (BV) has demonstrated significant efficacy in the initial induction therapy, post-transplant maintenance/consolidation therapy, and treatment of R/R HL, establishing itself as one of the standard treatment options for HL patients.